Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Mini Rev Med Chem. 2011 May;11(5):390–398. doi: 10.2174/138955711795445880

Anabolic Androgenic Steroids and Intracellular Calcium Signaling: A Mini Review on Mechanisms and Physiological Implications

JM Vicencio 1,2, M Estrada 1,3, D Galvis 1, R Bravo 1, AE Contreras 1, D Rotter 4, G Szabadkai 2, JA Hill 4, BA Rothermel 4, E Jaimovich 1,3, S Lavandero 1,3,*
PMCID: PMC4416211  NIHMSID: NIHMS684234  PMID: 21443511

Abstract

Increasing evidence suggests that nongenomic effects of testosterone and anabolic androgenic steroids (AAS) operate concertedly with genomic effects. Classically, these responses have been viewed as separate and independent processes, primarily because nongenomic responses are faster and appear to be mediated by membrane androgen receptors, whereas long-term genomic effects are mediated through cytosolic androgen receptors regulating transcriptional activity. Numerous studies have demonstrated increases in intracellular Ca2+ in response to AAS. These Ca2+ mediated responses have been seen in a diversity of cell types, including osteoblasts, platelets, skeletal muscle cells, cardiac myocytes and neurons. The versatility of Ca2+ as a second messenger provides these responses with a vast number of pathophysiological implications. In cardiac cells, testosterone elicits voltage-dependent Ca2+ oscillations and IP3R-mediated Ca2+ release from internal stores, leading to activation of MAPK and mTOR signaling that promotes cardiac hypertrophy. In neurons, depending upon concentration, testosterone can provoke either physiological Ca2+ oscillations, essential for synaptic plasticity, or sustained, pathological Ca2+ transients that lead to neuronal apoptosis. We propose therefore, that Ca2+ acts as an important point of crosstalk between nongenomic and genomic AAS signaling, representing a central regulator that bridges these previously thought to be divergent responses.

Keywords: Androgens, Ca2+, cardiac myocytes, heart, genomic, neurons, nongenomic, skeletal muscle cells, testosterone

1. INTRODUCTION

Second messengers are ions or molecules responsible for the transduction of extracellular signals into cellular processes. Among these, the Ca2+ ion is the most ubiquitous second messenger signal in eukaryotic systems and represents one of the most complex messages decoded by cells. Over the past decades, the study of intracellular Ca2+ has evolved from the observational study of Ca2+ transients inside different types of cells to becoming the basis of a vast array of physiological and pathological processes. For instance, we currently know that cardiac function depends almost entirely on fine-tuning of intracellular Ca2+, which when imbalanced leads to arrhythmias, cardiac failure or stroke. In neurons, Ca2+ regulates many processes including gene expression or the synaptic release of vesicles. In these, and many other types of cells, the regulation of intracellular Ca2+ is key for the determination of life-death outcomes, which contribute to neuropathies, cell death or tumorigenesis. Therefore, understanding the physiology of Ca2+-regulated processes is essential for finding new approaches to the treatment of human diseases including those of highest mortality in developed countries: cardiovascular disease, cancer and neurodegeneration, as well as many other genetic or endocrine disorders.

Steroidal hormones such as testosterone and its derivatives are well known for their androgenic properties and anabolic effects. The cumulative effect of these hormones is to direct the differentiation of organs and tissues toward the adoption of male phenotypes. Classically, anabolic androgenic steroids (AAS) act through binding to androgen receptors (AR), which once bound by their ligands, function as nuclear transcription factors promoting the expression of genes under the control of steroid-response elements (SRE). This programmed gene expression is achieved within a time course of hours after AAS binding to ARs. More recently, however, it has been described that steroidal hormones including AAS can also provoke faster responses, which do not involve gene expression. These effects have been termed as ‘nongenomic’, and they cover a wide range of intracellular processes such as the activation of membrane bound receptors, triggering of downstream pathways that involve protein kinases and phosphatases, mobilization of intracellular Ca2+, as well SRE-independent changes in transcription [1]. The origin of these responses has been attributed to AR-AAS complexes present in caveolin-enriched zones of the plasma membrane [2], however, recent studies identify orphan candidates for membrane-bound AR that after binding to AAS, trigger activation of intracellular second messengers [3]. This fascinating emerging topic will certainly contribute to our understanding of the pathophysiological consequences of androgen action. In the next sections, we will focus our attention in those nongenomic actions of AAS that are related to Ca2+ signaling, with emphasis on such effects on cardiac muscle cells, skeletal muscle cells and neurons. We will discuss the mechanistic pathways involved, their pathological implications and their perspectives.

2. AAS AND CALCIUM

2.1. Brief Description of Cellular Ca2+ Toolkits

Cellular Ca2+ signals possess the unique features of spatial compartmentalization and temporality, which together determines the message they carry and therefore the response they evoke. For instance, very fast (milliseconds) and localized Ca2+ increases allow the fusion of presynaptic vesicles with the plasma membrane, leading to neurotransmitter release or receptor externalization. During muscle contraction, a series of complex, compartmentalized and sequential Ca2+ events provide a mechanism for the decoding of a depolarizing signal into the contraction of sarcomere fibers within fractions of seconds, a process known as excitation-contraction (EC) coupling. On another hand, Ca2+ waves propagated across the cytoplasm of many different cell types lead to the activation of Ca2+-sensitive effectors, which include Ca2+-binding proteins, Ca2+-sensitive kinases and Ca2+-sensitive transcription factors. Once initiated, these processes can operate in a temporal range that covers milliseconds, minutes and even hours in the case of gene expression. Such localized Ca2+ signals are tightly controlled by a highly specialized molecular toolkit, capable of increasing Ca2+ concentrations in specific zones of the cytosol or the nucleus, and of removing it very rapidly (for details please see [4]).

Briefly, Ca2+ can be either introduced to the cytosol from the extracellular medium, or released from internal Ca2+ stores such as the sarco-endoplasmic reticulum. Several different Ca2+ channels reside in the plasma membrane, and in response to a variety of stimuli, they increase their open probability state, allowing the influx of Ca2+ ions. Among these channels, the family of voltage dependent L-type Ca2+ channels is of interest here, because they are expressed in neurons, myotubes and cardiomyocytes, and constitute the first element to respond to a depolarizing signal. Upon opening, they produce localized cytoplasmic Ca2+ sparklets, which can be sensed by another Ca2+ channel resident in the endoplasmic reticulum (ER) or sarcoplasmic reticulum (SR), known as the ryanodine receptor (RyR). In the case of neurons, type 1 RyRs respond by releasing Ca2+ from the ER in the form of syntilla, which allows the fusion of presynaptic vesicles with the plasma membrane and the release of neurotransmitters or hormones. In the case of cardiomyocytes, the opening of type 2 RyRs after a sparklet leads to SR Ca2+ release in the form of sparks, which stimulate the contraction of sarcomeres resulting in muscle contraction. In skeletal muscle and cultured myotubes, there is a direct interaction between L-type Cav1.1 channels and type 1 RyR facilitating the triggering of Ca2+ release.

Another ER-resident Ca2+ channel is the inositol 1,4,5-trisphosphate receptor (IP3R). Unlike RyRs, these channels do not crosstalk with L-type Ca2+ channels. Instead, they are ligand-activated in response to inositol 1,4,5-trisphosphate (IP3), which is produced in the inner face of the plasma membrane by the enzyme phospholipase C (PLC). Several isoforms of PLC exist, according to the type of plasma membrane receptor to which they are coupled. Once IP3 is bound to IP3Rs, these channels respond by releasing Ca2+ from the ER in the form of puffs into the cytosol and/or into the nucleus. These localized events lead to the activation of several effectors, including Ca2+-binding proteins such as calmodulin, enzymes such as calcineurin and calmodulin kinase, as well as Ca2+-sensitive transcription factors such as NFAT or CREB [5, 6]. Ca2+ can also be propagated throughout the cytoplasm in the form of waves through a crosstalk between aligned IP3Rs, in which Ca2+ itself increases the opening probability of surrounding IP3Rs.

The mechanisms to extrude Ca2+ from the cytosol include ATP-dependent pumps, such as the plasma membrane and the sarco-endoplasmic reticulum Ca2+ ATPases (PMCAs and SERCAs respectively), as well as the plasma membrane Na+/Ca2+ exchanger (NCX). Mitochondria represent an additional Ca2+ buffering organelle, as a substantial load of Ca2+ released from the ER is driven into the mitochondrial matrix by the voltage-dependent anion channel (VDAC) and the mitochondrial Ca2+ uniporter (MCU). In this way, Ca2+ is removed rapidly from the cytosol, thus shaping an undetermined set of Ca2+ signals that encode a vast array of messages (Fig. 1). For instance, slow Ca2+ signals in the cytoplasm and nuclei after electrical stimulation of skeletal myotubes depend on IP3 receptors [79]. This slow Ca2+ signal is also modulated by mitochondria [10], and activates a specific program of gene expression. Equivalent signals have been observed in adult skeletal muscle fibers [11].

Fig. 1.

Fig. 1

Intracellular Ca2+ signaling at a glance. (A) General vision of the basic Ca2+ toolkit. Mechanisms that drive Ca2+ into the cytosol from the extracellular medium include ligand-gated Ca2+ channels (not shown) and voltage-dependent Ca2+ channels (VDCC). Ca2+-release mechanisms from intracellular stores include inositol 1,4,5-trisphosphate receptors (IP3R), ryanodine receptors (RyR) and the mitochondrial Na+/Ca2+ exchanger (NCX). Mechanisms to extrude Ca2+ from the cytosol include the plasma membrane NCX, the plasma membrane and the sarco-endoplasmic reticulum Ca2+-ATPases (PMCA and SERCA, respectively), as well as the mitochondrial outer membrane voltage dependent anion channel (VDAC) and the mitochondrial inner membrane Ca2+ uniporter (MCU). (B) Ca2+ microdomains regulate neurotransmitter release in neurons. L-Type Ca2+ channels (LTCC) introduce Ca2+ into the cytosol in the form of sparklets, which directly induce local vesicle fusion with the terminal, or activate RyRs to open and release higher amounts of Ca2+ from the endoplasmic reticulum (ER) in the form of syntilla, which elicits massive neurotransmitter release. (C) Ca2+ microdomains regulate sarcomere contraction in skeletal and cardiac muscle cells. Depolarizing signals in T tubules induce opening of LTCCs. The resulting sparklet stimulates the opening of RyRs in these cells, which release Ca2+ in the form of sparks. This Ca2+ increase propagates as Ca2+ waves to generate muscle contraction. (D) The general mechanism for IP3R-mediated Ca2+ release in response to G protein-coupled protein receptors (GPCR) involves activation of phospholipase C (PLC) and local production of IP3, which activates IP3Rs to release high amounts of Ca2+ from the ER in the form of puffs. These signals lead to activation of Ca2+-dependent effectors in the cytosol, including calmodulin (CaM), calcineurin (CN) and mitogen-activated protein kinases (MAPK), among others. The propagation of puffs also leads to Ca2+ waves, which encode different messages according to their amplitude and frequency. Nuclear IP3R-mediated Ca2+ puffs or waves, lead to the activation of Ca2+-dependent transcription factors, as illustrated.

2.2. Acute Effects of AAS on Intracellular Ca2+

Before focusing on the relationship between steroids and intracellular Ca2+, one particular aspect of this relationship is the direct effect of AAS on Ca2+ channels. Increasing evidence indicates that L-type calcium channels are regulated by AAS in two different ways: acutely, by a direct antagonistic effect of AAS upon L-type Ca2+ channels, and chronically, after a genomic response that leads to increased expression of L-type Ca2+ channels [12, 13]. Relative to the structure-activity relationship, the Peers’ group seems to have done the most research on this subject, using HEK 293Ar75 cells [1416]. In a series of patch clamp experiments, among the different steroids tested, only testosterone blocked L-type calcium channels. There are three interesting observations to highlight these findings, the first one being that despite the structural similarity among all steroids assayed, only testosterone blocked the channel; second, considering the structural requirements, none of these structures resembles those of established Ca2+ channel blockers such as dihydropyridines, phenylalkylamines or benzothiazepines; and third, the researchers suggest that testosterone and nifedipine share common molecular requirements for inhibition of L-type Ca2+ channels in the S5 region of domain III [15]. It is important to note that the binding sites described for dihydropyridines are in segments 5 and 6 of domain III, and 6 of domain IV [17]. However, no specific binding region has been identified for AASs so far. Irrespective of these details, the acute effects of androgens upon L-type Ca2+ channels provide a potentially useful clinical strategy for the treatment of myocardial ischemia [18], coronary artery disease [19, 20], as well as for the reduction of cholesterol and visceral adiposity [2123]. These effects resemble those of third generation dihydropyridines such as amlodipine; further structural studies will contribute to the elucidation of the direct mechanisms involved in these responses. Thus far, the effects of androgens on the cardiovascular system remain incompletely understood, and some studies point to increased cardiovascular risk associated with high circulating androgen levels [24, 25], which is related to genomic responses that lead to cardiomyocyte hypertrophy [26], high L-type Ca2+ channel expression [12] and blood pressure [27, 28]. That said, other studies support a long-term cardioprotective role [29, 30]. Despite these differences, increasing clinical evidence supports consideration of transient use of testosterone derivatives to improve cardiovascular and pulmonary status [31].

2.3. Calcium-Mediated Myocyte Hypertrophy

The role of Ca2+ in mediating hypertrophy of cardiomyocytes and skeletal muscle cells has been well documented [32, 33]. Intracellular Ca2+ elevations trigger myocyte hypertrophic signaling via the phosphatase calcineurin, activation of the transcription factor NFAT [34] and the cyclic T-cdk9 complex [35]. Other transcription factors such as CAMTA2 are essential for regulating cardiac hypertrophy in response to calmodulin signaling, via the association with class II histone deacetylases (HDACs) [36]. Among the other Ca2+-dependent transcription factors involved in myocyte hypertrophy is CREB [37] and MEF2C [38, 39]. Interestingly, the AR has also been shown to induce myocyte hypertrophy [40] and independently, to regulate the activity of MEF2C [41], which is also regulated by calcineurin [42]. Therefore, a reasonable and predicted link between these processes could be mediated by androgen-induced Ca2+ signaling. Interestingly, Ca2+ triggers cardiac hypertrophy in response to several other agents including angiotensin II, endothelin-1, α-adrenergic agents and mechanical stretching [43]. However, it is currently unknown how androgens regulate signal transduction cascades during cardiac hypertrophy, and Ca2+ is a prominent mechanism that could drive these effects in the heart and in skeletal muscle cells.

Nongenomic testosterone effects have been observed in skeletal muscle cells, via the release of Ca2+ from internal stores [44, 45]. This Ca2+-wave signal involved a G protein-coupled membrane receptor and the activation of PLC with IP3 production and IP3R-mediated Ca2+ release from internal stores. Ca2+ release induced by testosterone also activates a Ras/MEK/ERK pathway, which is known to be involved in the extracellular response to growth factors that elicit hypertrophic processes in myocytes [46]. In cardiac myocytes, these effects were mimicked by cell-impermeant testosterone complexed to albumin (T-BSA), and were not inhibited by the intracellular AR antagonist cyproterone. This result suggest that a membrane-resident AR different from the classic AR mediates these responses. Interestingly, this Ca2+ signal was complex and demonstrated to contain at least 3 components [47]. First, in the presence of extracellular Ca2+, cardiac myocytes stimulated with testosterone enhanced their basal Ca2+ levels via a mechanism that involves L-type Ca2+ channels. Second, the magnitude of the basal Ca2+ oscillations was enhanced by testosterone, in a pathway that involves crosstalk between L-type Ca2+ channels and RyRs. Third, in the absence of extracellular Ca2+, cardiac myocytes evidenced a Gβγ/PLC/IP3/IP3R pathway that leads to a nuclear Ca2+ with kinetics faster than the cytosolic Ca2+ increases.

From these responses, multiple perspectives emerge. On one hand, the cardiomyocyte contraction process mediated by Ca2+-induced Ca2+ release could be inotropically enhanced, as the basal oscillations were increased in magnitude but not in frequency. On the other hand, the increase in nuclear Ca2+ is likely to be involved in the modulation of gene expression. Further elucidation of these processes will certainly reveal new pathways in the hypertrophic response of cardiac myocytes to AAS. However, new insights have already been obtained regarding the relationship between cytosolic Ca2+ levels and the activation of the mammalian target of rapamycin (mTOR) complex 1, which is a master regulator of cell growth by transcriptional activity and protein synthesis [48]. In cultured cardiac myocytes, both the MEK/ERK pathway and the mTOR/S6K axis are stimulated by testosterone, leading to increased cell size, amino acid incorporation, and augmented expression of β-myosin heavy chain and αskeletal actin in an IP3R/Ca2+-dependent fashion [26]. These results lend yet more evidence to a model where Ca2+ serves as a novel central regulator of cardiac myocyte hypertrophy in response to AAS. Thus, nongenomic responses mediated by Ca2+ operate in concert with transcriptional responses, establishing a functional link between these processes which were previously thought to be independent (Fig. 2). In concordance with these findings, the non-permeant T-BSA complex has been shown to promote actin cytoskeleton reorganization via nongenomic responses in prostate cancer cells [49]. Additionally, Ca2+ transients have been reported to increase the binding of testosterone to intracellular ARs [50]. Further studies will elucidate more details of the triangular interplay among androgens, Ca2+ and hypertrophy, in particular regarding the participation of classical hypertrophy-related transcription factors. With time, we expect these insights to be relevant to skeletal muscle cells as well.

Fig. 2.

Fig. 2

Effects of AAS on intracellular calcium. In myotubes, as well as in cardiomyocytes, testosterone activates plasma membrane androgen receptors (MAR) coupled to heterotrimeric Gq protein. Gβγ dimers activate phospholipase C (PLC), which locally produces inositol 1,4,5-trisphosphate (IP3) thus activating IP3 receptors (IP3R). The consequent Ca2+ increase leads to the activation of several pathways, including the MEK/ERK/mTOR axis, propagation of nuclear Ca2+ signals and modulation of intracellular AR affinity for testosterone (an effect observed in platelets). These responses combined induce a series of genomic changes that lead to increased gene expression and increased protein synthesis, ultimately leading to cardiac hypertrophy. Although not studied in further detail, the effect at the left side of the figure upon Ca2+ release from ryanodine receptors (RyR), might lead to inotropy and therefore contribute via nongenomic changes to the hypertrophic phenotype. An overview of these processes is presented in the lower part of the figure, which illustrates how Ca2+ is centrally regulating the crosstalk between nongenomic and genomic responses.

2.4. Calcium Oscillations and Neuronal Apoptosis

The brain represents a hallmark target site for the action of steroidal hormones. Both adrenal and gonadal steroids play important roles in brain development and function via genomic and nongenomic mechanisms [1, 5155]. In addition, neurons constitute an elegant and complex model for the study of Ca2+ signals, mainly because Ca2+ regulates essential neural processes including synaptic plasticity [56], exocytosis [57], gene expression [58, 59], bioenergetics [60], autophagy [61] and apoptosis [62]. It has been described that estrogen promotes survival of neurons [63]; and mitochondrial Ca2+ levels seem to participate in these responses via metabolic mechanisms [64]. In contrast, testosterone may exert opposite effects upon neuronal survival, for instance by decreasing neural function and the mass of dopaminergic neurons in animal models [65]. These findings are consistent with the neuronal loss observed on human AAS abusers [66], as well as with the augmented risk of developing psychiatric disorders among these individuals [67]. On the other hand, it has been described that high doses of AAS induce apoptotic cell death in cardiac myocytes [68]. Interestingly, testosterone-driven changes in intracellular Ca2+ levels are similar in cardiac myocytes and neurons, namely rapid increase in Ca2+ oscillations.

Ca2+ oscillations represent, in comparison to single Ca2+ transients, a more complex signal to decode by cells, basically because they contain additional information encoded in their frequency and amplitude (for more details, please read [69]). These two parameters have been reported to activate transcriptional genomic responses [70, 71], mediate cardiac hypertrophy [72], or to enhance dendritic growth in neurons [73]. Transient testosterone addition to human neuroblastoma cells produces rapid intracellular Ca2+ oscillations that correlated with an increase in neurite growth. This response is dependent on concerted interactions between Ca2+ release through type-1 IP3Rs and Ca2+ influx from the extracellular medium [74]. Importantly, these responses were obtained with 100 nM testosterone, a concentration that is on the high circulating range observed in humans, and therefore depends on physiological conditions such as gender, the physical state, age, or brain aromatase levels. This increase in neurite growth might be related to brain development and brain plasticity events observed with advanced age. However, higher testosterone levels are usually found among individuals exposed to testosterone replacement therapy or AAS abuse. In concordance with this notion, it has been observed that concentrations of 1–10 μM testosterone lead to higher and sustained Ca2+ signals that produce neuronal apoptosis [75]. This neuronal cell death cascade requires caspase activation and is inhibited by pharmacological inhibition or siRNA-mediated depletion of type-1 IP3Rs. Therefore, a dual response is produced by testosterone on neuronal cells, on one hand promoting synaptic plasticity at physiological concentrations, and on the other hand, leading to apoptosis at higher concentrations (Fig. 3). Further details of these mechanisms are urgently needed to understand these effects in terms of the genetic responses involved, the possible adaptative mechanisms to chronic androgen administration and the clinical consequences in individuals exposed to high levels of androgens.

Fig. 3.

Fig. 3

Implications of Ca2+ oscillations in a neuronal model of AAS abuse. The study on the effects of testosterone upon neuroblastoma cells has provided two models for androgen action. (A) At physiological concentrations (nM), testosterone elicits intracellular Ca2+ oscillations, which are turned ‘on’ by inositol 1,4,5-trisphosphate receptor (IP3R)-mediated Ca2+ release, and are turned ‘off’ by Ca2+ extruding mechanisms. These oscillations lead to an increase in neurite overgrowth, which might be related to synaptic plasticity. (B) At pathological concentrations (μM), testosterone persistence leads to enhanced activation of membrane androgen receptors (MAR), which lead to a sustained turning ‘on’ of the Ca2+ signal. Under these conditions, mitochondrial-dependent cascades of caspase activation lead to neuronal apoptosis.

2.5. Circadian Regulation of AAS Signaling

There is a growing appreciation for the importance of circadian rhythms in human health and disease. These 24-hour cycles anticipate changes in physiological demand and help to coordinate appropriate responses or provide temporal separation of opposing but equally important processes. In the case of AAS, there is evidence of circadian control at many levels ranging from timing of hormone release and receptor availability, to circadian changes in intercellular Ca2+ levels. Conversely, testosterone can influence circadian day length and accordingly, sustained use of AAS has been associated with hyperactivity and disruption of circadian rhythm [76]. It is likely that this cross-regulation between AAS and circadian rhythms involves both genomic and nongenomic mechanisms of action, however, for the sake of this review we will touch briefly on the potential involvement of Ca2+ signaling. Cytoplasmic Ca2+ levels are circadian in a number of tissues including the suprachiasmatic nucleus (SCN), the region of the brain where the central clock mechanism resides, and Ca2+ acts as an important second messenger during clock resetting [77]. Immerging studies suggest that normally in the healthy heart, diastolic cytoplasmic Ca2+ levels are also circadian, which results in circadian activation of calcineurin and NFAT [78]. Cardiac myocytes require repair and maintenance, and this is most likely occurring during times of lower demand [79]. In mice, the peak observed in cardiac calcineurin/NFAT activity occurs at the beginning of the animal’s resting phase and activation of this pathway is an important component of cardiac remodeling. Consistent with concept of cardiac rhythms in Ca2+ signaling, isolated adult cardiomyocytes display circadian variation in the magnitude of Ca2+ release in response to isoproterenol [80]. Similarly, both brain [81] and cardiac [82] tissue display diurnal rhythms in susceptibility to ischemic damage. As circulating levels of AAS are circadian, it is essential to consider their potential involvement in coordination of anabolic, catabolic, and cell survival cycles in order to fully understand their mechanism of action in vivo.

3. SUMMARY AND CONCLUDING REMARKS

Genomic responses of androgens, acting via binding to intracellular AR and changes in transcription, take hours to manifest, whereas a new set of rapid responses, termed ‘nongenomic,’ has been widely reported. Among the rapid effects of androgens, changes in intracellular Ca2+ represent a particularly powerful signaling mechanism, because Ca2+ is a central mediator of a diverse array of cell responses including entrainment and maintenance of circadian rhythmicity. In both skeletal muscle cells and cardiac muscle cells, testosterone elicits a rapid release of Ca2+ from IP3-dependent and IP3-independent stores, which are related to ERK signaling, mTOR signaling, gene expression and possible inotropic effects [26, 44, 47]. Together, these responses lead to myocyte hypertrophy, thus bridging nongenomic and genomic responses via established Ca2+-dependent mechanisms. On the other hand, neurons are also a target for the action of steroidal hormones, and testosterone regulates several processes depending on its concentration. At physiological levels (nM), testosterone produces Ca2+ oscillations mediated by IP3Rs and Ca2+ influx. These oscillations are responsible for enhancing neurite growth and thus might regulate synaptic plasticity during development or brain damage events. At pharmacological concentrations (μM), such as those found in individuals with androgen replacement therapy or AAS abuse, testosterone leads to prolonged and sustained Ca2+ transients, which unleash mitochondrial dependent caspase activation mechanisms and lead to neuronal apoptosis [74, 75]. With respect to the adverse cardiovascular consequences of chronic AAS treatment, these studies also provide new insights into the mechanisms responsible for increased blood pressure, increased risk of pathological cardiac hypertrophy, arrhythmias and stroke [24, 83]. Furthermore, due to the diversity of levels at which circadian-regulated processes can influence and cross-talk with AAS signaling, we propose that it will be essential to integrate circadian influences with genomic and nongenomic effects to fully understand the impact of AAS in vivo.

Thus far, intracellular Ca2+ signaling represents a significant and potentially new important effect of AAS in muscle cells, neurons and possibly many other cell types. Additional insights into the implication of these effects upon gene expression and long-term genomic responses are urgently needed, and are likely to reveal unexpected physiologically relevant links between nongenomic and genomic responses to androgenic steroids.

Acknowledgments

Acknowledgements and apologies are expressed to the scientists whose work was not cited here. This work was supported by FONDECYT [grant 1090276 to M.E. and grant 1080436 to S.L.], FONDAP [grant 15010006 to M.E., E.J. and S.L.], by the National Institutes of Health (to J.A.H. and B.A.R.), the American Heart Association (to M.I., J.A.H., and B.A.R.), the American Heart Association-Jon Holden DeHaan Foundation (to J.A.H.). R.B. is a Conicyt doctoral fellow. J.M.V. and A.E.F. hold a postdoctoral fellowship from Becas Chile and FONDECYT, respectively.

ABBREVIATIONS

AAS

anabolic androgenic steroids

AR

androgen receptor

Ca2+

calcium

[Ca2+]

Ca2+ concentration

E-C

excitation-contraction

ER

endoplasmic reticulum

ERK

extracellular-regulated kinase

HDAC

histone deacetylase complex

IP3

inositol-1,4,5-trisphosphate

IP3R

IP3 receptor

LTCC

L-type Ca2+ channel

MAPK

mitogen-activated protein kinases

MAR

membrane AR

MCU

mitochondrial Ca2+ uniporter

mTOR

mammalian target of rapamycin

NCX

Na+/Ca2+ exchanger

PIP2

phosphatidylinositol 4,5-bisphosphate

PLC

phospholipase C

PMCA

plasma membrane Ca2+ ATPase

RyR

ryanodine receptor

SERCA

sarco-endoplasmic reticulum Ca2+ ATPase

SR

sarcoplasmic reticulum

T-BSA

testosterone covalently bound to albumin

VDAC

voltage-dependent anionic channel

VDCC

voltage-dependent Ca2+ channel

SCN

suprachiasmatic nucleus

S6K

ribosomal protein S6 p70 kinase

4E-BP1

translation initiation factor 4E binding protein 1

References

  • 1.Michels G, Hoppe UC. Rapid actions of androgens. Front Neuroendocrinol. 2008;29:182–198. doi: 10.1016/j.yfrne.2007.08.004. [DOI] [PubMed] [Google Scholar]
  • 2.Lu ML, Schneider MC, Zheng Y, Zhang X, Richie JP. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem. 2001;276:13442–13451. doi: 10.1074/jbc.M006598200. [DOI] [PubMed] [Google Scholar]
  • 3.Pi M, Parrill AL, Quarles LD. GPRC6A mediates the non-genomic effects of steroids. J Biol Chem. 2010;285(51):39953–64. doi: 10.1074/jbc.M110.158063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4:517–529. doi: 10.1038/nrm1155. [DOI] [PubMed] [Google Scholar]
  • 5.Vlasblom R, Muller A, Musters RJ, Zuidwijk MJ, Van Hardeveld C, Paulus WJ, Simonides WS. Contractile arrest reveals calcium-dependent stimulation of SERCA2a mRNA expression in cultured ventricular cardiomyocytes. Cardiovasc Res. 2004;63:537–544. doi: 10.1016/j.cardiores.2004.04.005. [DOI] [PubMed] [Google Scholar]
  • 6.Arguin G, Caron AZ, Elkoreh G, Denault JB, Guillemette G. The transcription factors NFAT and CREB have different susceptibilities to the reduced Ca2+ responses caused by the knock down of inositol trisphosphate receptor in HEK 293A cells. Cell Physiol Biochem. 2010;26:629–640. doi: 10.1159/000322330. [DOI] [PubMed] [Google Scholar]
  • 7.Buvinic S, Almarza G, Bustamante M, Casas M, Lopez J, Riquelme M, Saez JC, Huidobro-Toro JP, Jaimovich E. ATP released by electrical stimuli elicits calcium transients and gene expression in skeletal muscle. J Biol Chem. 2009;284:34490–34505. doi: 10.1074/jbc.M109.057315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Cardenas C, Liberona JL, Molgo J, Colasante C, Mignery GA, Jaimovich E. Nuclear inositol 1,4,5-trisphosphate receptors regulate local Ca2+ transients and modulate cAMP response element binding protein phosphorylation. J Cell Sci. 2005;118:3131–3140. doi: 10.1242/jcs.02446. [DOI] [PubMed] [Google Scholar]
  • 9.Eltit JM, Garcia AA, Hidalgo J, Liberona JL, Chiong M, Lavandero S, Maldonado E, Jaimovich E. Membrane electrical activity elicits inositol 1,4,5-trisphosphate-dependent slow Ca2+ signals through a Gbetagamma/phosphatidylinositol 3-kinase gamma pathway in skeletal myotubes. J Biol Chem. 2006;281:12143–12154. doi: 10.1074/jbc.M511218200. [DOI] [PubMed] [Google Scholar]
  • 10.Eisner V, Parra V, Lavandero S, Hidalgo C, Jaimovich E. Mitochondria fine-tune the slow Ca(2+) transients induced by electrical stimulation of skeletal myotubes. Cell Calcium. 2010;48:358–370. doi: 10.1016/j.ceca.2010.11.001. [DOI] [PubMed] [Google Scholar]
  • 11.Casas M, Figueroa R, Jorquera G, Escobar M, Molgo J, Jaimovich E. IP(3)-dependent, post-tetanic calcium transients induced by electrostimulation of adult skeletal muscle fibers. J Gen Physiol. 2010;136:455–467. doi: 10.1085/jgp.200910397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Er F, Gassanov N, Brandt MC, Madershahian N, Hoppe UC. Impact of dihydrotestosterone on L-type calcium channels in human ventricular cardiomyocytes. Endocr Res. 2009;34:59–67. doi: 10.1080/07435800903136953. [DOI] [PubMed] [Google Scholar]
  • 13.Er F, Michels G, Brandt MC, Khan I, Haase H, Eicks M, Lindner M, Hoppe UC. Impact of testosterone on cardiac L-type calcium channels and Ca2+ sparks: acute actions antagonize chronic effects. Cell Calcium. 2007;41:467–477. doi: 10.1016/j.ceca.2006.09.003. [DOI] [PubMed] [Google Scholar]
  • 14.Hall J, Jones RD, Jones TH, Channer KS, Peers C. Selective inhibition of L-type Ca2+ channels in A7r5 cells by physiological levels of testosterone. Endocrinology. 2006;147:2675–2680. doi: 10.1210/en.2005-1243. [DOI] [PubMed] [Google Scholar]
  • 15.Scragg JL, Dallas ML, Peers C. Molecular requirements for L-type Ca2+ channel blockade by testosterone. Cell Calcium. 2007;42:11–15. doi: 10.1016/j.ceca.2006.11.003. [DOI] [PubMed] [Google Scholar]
  • 16.Scragg JL, Jones RD, Channer KS, Jones TH, Peers C. Testosterone is a potent inhibitor of L-type Ca(2+) channels. Biochem Biophys Res Commun. 2004;318:503–506. doi: 10.1016/j.bbrc.2004.04.054. [DOI] [PubMed] [Google Scholar]
  • 17.Wappl E, Mitterdorfer J, Glossmann H, Striessnig J. Mechanism of dihydropyridine interaction with critical binding residues of L-type Ca2+ channel alpha 1 subunits. J Biol Chem. 2001;276:12730–12735. doi: 10.1074/jbc.M010164200. [DOI] [PubMed] [Google Scholar]
  • 18.Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res. 1999;84:813–819. doi: 10.1161/01.res.84.7.813. [DOI] [PubMed] [Google Scholar]
  • 19.English KM, Jones RD, Jones TH, Morice AH, Channer KS. Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest. 2002;25:455–458. doi: 10.1007/BF03344037. [DOI] [PubMed] [Google Scholar]
  • 20.Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, della Monica PL, Bonfigli B, Volpe M, Chierchia SL. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 1999;99:1666–1670. doi: 10.1161/01.cir.99.13.1666. [DOI] [PubMed] [Google Scholar]
  • 21.Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899–906. doi: 10.1530/eje.1.02166. [DOI] [PubMed] [Google Scholar]
  • 22.Hanke H, Lenz C, Hess B, Spindler KD, Weidemann W. Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation. 2001;103:1382–1385. doi: 10.1161/01.cir.103.10.1382. [DOI] [PubMed] [Google Scholar]
  • 23.Duell PB, Bierman EL. The relationship between sex hormones and high-density lipoprotein cholesterol levels in healthy adult men. Arch Intern Med. 1990;150:2317–2320. [PubMed] [Google Scholar]
  • 24.Baggish AL, Weiner RB, Kanayama G, Hudson JI, Picard MH, Hutter AM, Jr, Pope HG., Jr Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circ Heart Fail. 2010;3:472–476. doi: 10.1161/CIRCHEARTFAILURE.109.931063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109–122. doi: 10.1056/NEJMoa1000485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Altamirano F, Oyarce C, Silva P, Toyos M, Wilson C, Lavandero S, Uhlen P, Estrada M. Testosterone induces cardiomyocyte hypertrophy through mammalian target of rapamycin complex 1 pathway. J Endocrinol. 2009;202:299–307. doi: 10.1677/JOE-09-0044. [DOI] [PubMed] [Google Scholar]
  • 27.Schwarcz MD, Frishman WH. Testosterone and coronary artery disease. Cardiol Rev. 2010;18:251–257. doi: 10.1097/CRD.0b013e3181e84673. [DOI] [PubMed] [Google Scholar]
  • 28.Schofield RS, Hill JA, McGinn CJ, Aranda JM. Hormone therapy in men and risk of cardiac allograft rejection. J Heart Lung Transplant. 2002;21:493–495. doi: 10.1016/s1053-2498(01)00366-7. [DOI] [PubMed] [Google Scholar]
  • 29.Bourghardt J, Wilhelmson AS, Alexanderson C, De Gendt K, Verhoeven G, Krettek A, Ohlsson C, Tivesten A. Androgen receptor-dependent and independent atheroprotection by testosterone in male mice. Endocrinology. 2010;151:5428–5437. doi: 10.1210/en.2010-0663. [DOI] [PubMed] [Google Scholar]
  • 30.Torkler S, Wallaschofski H, Baumeister SE, Volzke H, Dorr M, Felix S, Rettig R, Nauck M, Haring R. Inverse association between total testosterone concentrations, incident hypertension and blood pressure. Aging Male. 2010 doi: 10.3109/13685538.2010.529194. In press. [DOI] [PubMed] [Google Scholar]
  • 31.Naghi JJ, Philip KJ, Dilibero D, Willix R, Schwarz ER. Testosterone therapy: treatment of metabolic disturbances in heart failure. J Cardiovasc Pharmacol Ther. 2011;16(1):14–23. doi: 10.1177/1074248410378121. [DOI] [PubMed] [Google Scholar]
  • 32.Alves ML, Gaffin RD, Wolska BM. Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes. J Mol Cell Cardiol. 2010;48:834–842. doi: 10.1016/j.yjmcc.2010.01.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Sakuma K, Yamaguchi A. The functional role of calcineurin in hypertrophy, regeneration, and disorders of skeletal muscle. J Biomed Biotechnol. 2010;2010:721219. doi: 10.1155/2010/721219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Schulz RA, Yutzey KE. Calcineurin signaling and NFAT activation in cardiovascular and skeletal muscle development. Dev Biol. 2004;266:1–16. doi: 10.1016/j.ydbio.2003.10.008. [DOI] [PubMed] [Google Scholar]
  • 35.van Empel VP, De Windt LJ. Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res. 2004;63:487–499. doi: 10.1016/j.cardiores.2004.02.013. [DOI] [PubMed] [Google Scholar]
  • 36.Song K, Backs J, McAnally J, Qi X, Gerard RD, Richardson JA, Hill JA, Bassel-Duby R, Olson EN. The transcriptional coactivator CAMTA2 stimulates cardiac growth by opposing class II histone deacetylases. Cell. 2006;125:453–466. doi: 10.1016/j.cell.2006.02.048. [DOI] [PubMed] [Google Scholar]
  • 37.Chiong M, Parra V, Eisner V, Ibarra C, Maldonado C, Criollo A, Bravo R, Quiroga C, Contreras A, Vicencio JM, Cea P, Bucarey JL, Molgo J, Jaimovich E, Hidalgo C, Kroemer G, Lavandero S. Parallel activation of Ca(2+)-induced survival and death pathways in cardiomyocytes by sorbitol-induced hyperosmotic stress. Apoptosis. 2010;15:887–903. doi: 10.1007/s10495-010-0505-9. [DOI] [PubMed] [Google Scholar]
  • 38.Xu J, Gong NL, Bodi I, Aronow BJ, Backx PH, Molkentin JD. Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice. J Biol Chem. 2006;281:9152–9162. doi: 10.1074/jbc.M510217200. [DOI] [PubMed] [Google Scholar]
  • 39.Munoz JP, Collao A, Chiong M, Maldonado C, Adasme T, Carrasco L, Ocaranza P, Bravo R, Gonzalez L, Diaz-Araya G, Hidalgo C, Lavandero S. The transcription factor MEF2C mediates cardiomyocyte hypertrophy induced by IGF-1 signaling. Biochem Biophys Res Commun. 2009;388:155–160. doi: 10.1016/j.bbrc.2009.07.147. [DOI] [PubMed] [Google Scholar]
  • 40.Marsh JD, Lehmann MH, Ritchie RH, Gwathmey JK, Green GE, Schiebinger RJ. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation. 1998;98:256–261. doi: 10.1161/01.cir.98.3.256. [DOI] [PubMed] [Google Scholar]
  • 41.Wyce A, Bai Y, Nagpal S, Thompson CC. Research Resource: The androgen receptor modulates expression of genes with critical roles in muscle development and function. Mol Endocrinol. 2010;24:1665–1674. doi: 10.1210/me.2010-0138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Roberts-Wilson TK, Reddy RN, Bailey JL, Zheng B, Ordas R, Gooch JL, Price SR. Calcineurin signaling and PGC-1alpha expression are suppressed during muscle atrophy due to diabetes. Biochim Biophys Acta. 2010;1803:960–967. doi: 10.1016/j.bbamcr.2010.03.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Frey N, McKinsey TA, Olson EN. Decoding calcium signals involved in cardiac growth and function. Nat Med. 2000;6:1221–1227. doi: 10.1038/81321. [DOI] [PubMed] [Google Scholar]
  • 44.Estrada M, Espinosa A, Muller M, Jaimovich E. Testosterone stimulates intracellular calcium release and mitogen-activated protein kinases via a G protein-coupled receptor in skeletal muscle cells. Endocrinology. 2003;144:3586–3597. doi: 10.1210/en.2002-0164. [DOI] [PubMed] [Google Scholar]
  • 45.Estrada M, Liberona JL, Miranda M, Jaimovich E. Aldosterone- and testosterone-mediated intracellular calcium response in skeletal muscle cell cultures. Am J Physiol Endocrinol Metab. 2000;279:E132–139. doi: 10.1152/ajpendo.2000.279.1.E132. [DOI] [PubMed] [Google Scholar]
  • 46.Lorenz K, Schmitt JP, Vidal M, Lohse MJ. Cardiac hypertrophy: targeting Raf/MEK/ERK1/2-signaling. Int J Biochem Cell Biol. 2009;41:2351–2355. doi: 10.1016/j.biocel.2009.08.002. [DOI] [PubMed] [Google Scholar]
  • 47.Vicencio JM, Ibarra C, Estrada M, Chiong M, Soto D, Parra V, Diaz-Araya G, Jaimovich E, Lavandero S. Testosterone induces an intracellular calcium increase by a nongenomic mechanism in cultured rat cardiac myocytes. Endocrinology. 2006;147:1386–1395. doi: 10.1210/en.2005-1139. [DOI] [PubMed] [Google Scholar]
  • 48.Hall MN. mTOR-what does it do? Transplant Proc. 2008;40:S5–8. doi: 10.1016/j.transproceed.2008.10.009. [DOI] [PubMed] [Google Scholar]
  • 49.Papakonstanti EA, Kampa M, Castanas E, Stournaras C. A rapid, nongenomic, signaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors. Mol Endocrinol. 2003;17:870–881. doi: 10.1210/me.2002-0253. [DOI] [PubMed] [Google Scholar]
  • 50.Cabeza M, Flores M, Bratoeff E, de la Pena A, Mendez E, Ceballos G. Intracellular Ca2+ stimulates the binding to androgen receptors in platelets. Steroids. 2004;69:767–772. doi: 10.1016/j.steroids.2004.09.006. [DOI] [PubMed] [Google Scholar]
  • 51.Remage-Healey L, Bass AH. Rapid, hierarchical modulation of vocal patterning by steroid hormones. J Neurosci. 2004;24:5892–5900. doi: 10.1523/JNEUROSCI.1220-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Evrard HC, Balthazart J. Rapid regulation of pain by estrogens synthesized in spinal dorsal horn neurons. J Neurosci. 2004;24:7225–7229. doi: 10.1523/JNEUROSCI.1638-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Balthazart J, Baillien M, Ball GF. Rapid and reversible inhibition of brain aromatase activity. J Neuroendocrinol. 2001;13:63–73. doi: 10.1046/j.1365-2826.2001.00598.x. [DOI] [PubMed] [Google Scholar]
  • 54.Park SY, Tournell C, Sinjoanu RC, Ferreira A. Caspase-3-and calpain-mediated tau cleavage are differentially prevented by estrogen and testosterone in beta-amyloid-treated hippocampal neurons. Neuroscience. 2007;144:119–127. doi: 10.1016/j.neuroscience.2006.09.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Vasudevan N, Pfaff DW. Non-genomic actions of estrogens and their interaction with genomic actions in the brain. Front Neuroendocrinol. 2008;29:238–257. doi: 10.1016/j.yfrne.2007.08.003. [DOI] [PubMed] [Google Scholar]
  • 56.Lohmann C. Calcium signaling and the development of specific neuronal connections. Prog Brain Res. 2009;175:443–452. doi: 10.1016/S0079-6123(09)17529-5. [DOI] [PubMed] [Google Scholar]
  • 57.Pang ZP, Sudhof TC. Cell biology of Ca2+-triggered exocytosis. Curr Opin Cell Biol. 2010;22:496–505. doi: 10.1016/j.ceb.2010.05.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Kemmerling U, Munoz P, Muller M, Sanchez G, Aylwin ML, Klann E, Carrasco MA, Hidalgo C. Calcium release by ryanodine receptors mediates hydrogen peroxide-induced activation of ERK and CREB phosphorylation in N2a cells and hippocampal neurons. Cell Calcium. 2007;41:491–502. doi: 10.1016/j.ceca.2006.10.001. [DOI] [PubMed] [Google Scholar]
  • 59.Marchenko SM, Thomas RC. Nuclear Ca2+ signalling in cerebellar Purkinje neurons. Cerebellum. 2006;5:36–42. doi: 10.1080/14734220600554438. [DOI] [PubMed] [Google Scholar]
  • 60.Abramov AY, Duchen MR. Impaired mitochondrial bioenergetics determines glutamate-induced delayed calcium deregulation in neurons. Biochim Biophys Acta. 2010;1800:297–304. doi: 10.1016/j.bbagen.2009.08.002. [DOI] [PubMed] [Google Scholar]
  • 61.Vicencio JM, Lavandero S, Szabadkai G. Ca2+, autophagy and protein degradation: thrown off balance in neurodegenerative disease. Cell Calcium. 2010;47:112–121. doi: 10.1016/j.ceca.2009.12.013. [DOI] [PubMed] [Google Scholar]
  • 62.Harr MW, Distelhorst CW. Apoptosis and autophagy: decoding calcium signals that mediate life or death. Cold Spring Harb Perspect Biol. 2010;2:a005579. doi: 10.1101/cshperspect.a005579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Gould E, McEwen BS. Neuronal birth and death. Curr Opin Neurobiol. 1993;3:676–682. doi: 10.1016/0959-4388(93)90138-o. [DOI] [PubMed] [Google Scholar]
  • 64.Nilsen J, Brinton RD. Mitochondria as therapeutic targets of estrogen action in the central nervous system. Curr Drug Targets CNS Neurol Disord. 2004;3:297–313. doi: 10.2174/1568007043337193. [DOI] [PubMed] [Google Scholar]
  • 65.Johnson ML, Day AE, Ho CC, Walker QD, Francis R, Kuhn CM. Androgen decreases dopamine neurone survival in rat midbrain. J Neuroendocrinol. 2010;22:238–247. doi: 10.1111/j.1365-2826.2010.01965.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Petersson A, Garle M, Holmgren P, Druid H, Krantz P, Thiblin I. Toxicological findings and manner of death in autopsied users of anabolic androgenic steroids. Drug Alcohol Depend. 2006;81:241–249. doi: 10.1016/j.drugalcdep.2005.07.003. [DOI] [PubMed] [Google Scholar]
  • 67.Kanayama G, Hudson JI, Pope HG., Jr Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern? Drug Alcohol Depend. 2008;98:1–12. doi: 10.1016/j.drugalcdep.2008.05.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Zaugg M, Jamali NZ, Lucchinetti E, Xu W, Alam M, Shafiq SA, Siddiqui MA. Anabolic-androgenic steroids induce apoptotic cell death in adult rat ventricular myocytes. J Cell Physiol. 2001;187:90–95. doi: 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1057>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  • 69.Uhlen P, Fritz N. Biochemistry of calcium oscillations. Biochem Biophys Res Commun. 2010;396:28–32. doi: 10.1016/j.bbrc.2010.02.117. [DOI] [PubMed] [Google Scholar]
  • 70.Dolmetsch RE, Xu K, Lewis RS. Calcium oscillations increase the efficiency and specificity of gene expression. Nature. 1998;392:933–936. doi: 10.1038/31960. [DOI] [PubMed] [Google Scholar]
  • 71.Li W, Llopis J, Whitney M, Zlokarnik G, Tsien RY. Cell-permeant caged InsP3 ester shows that Ca2+ spike frequency can optimize gene expression. Nature. 1998;392:936–941. doi: 10.1038/31965. [DOI] [PubMed] [Google Scholar]
  • 72.Colella M, Grisan F, Robert V, Turner JD, Thomas AP, Pozzan T. Ca2+ oscillation frequency decoding in cardiac cell hypertrophy: role of calcineurin/NFAT as Ca2+ signal integrators. Proc Natl Acad Sci USA. 2008;105:2859–2864. doi: 10.1073/pnas.0712316105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Desfrere L, Karlsson M, Hiyoshi H, Malmersjo S, Nanou E, Estrada M, Miyakawa A, Lagercrantz H, El Manira A, Lal M, Uhlen P. Na,K-ATPase signal transduction triggers CREB activation and dendritic growth. Proc Natl Acad Sci USA. 2009;106:2212–2217. doi: 10.1073/pnas.0809253106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Estrada M, Uhlen P, Ehrlich BE. Ca2+ oscillations induced by testosterone enhance neurite outgrowth. J Cell Sci. 2006;119:733–743. doi: 10.1242/jcs.02775. [DOI] [PubMed] [Google Scholar]
  • 75.Estrada M, Varshney A, Ehrlich BE. Elevated testosterone induces apoptosis in neuronal cells. J Biol Chem. 2006;281:25492–25501. doi: 10.1074/jbc.M603193200. [DOI] [PubMed] [Google Scholar]
  • 76.Hayes LD, Bickerstaff GF, Baker JS. Interactions of cortisol, testosterone, and resistance training: influence of circadian rhythms. Chronobiol Int. 2010;27:675–705. doi: 10.3109/07420521003778773. [DOI] [PubMed] [Google Scholar]
  • 77.Ikeda M. Calcium dynamics and circadian rhythms in suprachiasmatic nucleus neurons. Neuroscientist. 2004;10:315–324. doi: 10.1177/10738584031262149. [DOI] [PubMed] [Google Scholar]
  • 78.Sachan N, Dey A, Rotter D, Grinsfelder DB, Battiprolu PK, Sikder D, Copeland V, Oh M, Bush E, Shelton JM, Bibb JA, Hill JA, Rothermel BA. Sustained hemodynamic stress disrupts normal circadian rhythms in calcineurin-dependent signaling and protein phosphorylation in the heart. Circ Res. 2011;108:437–445. doi: 10.1161/CIRCRESAHA.110.235309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Boateng SY, Goldspink PH. Assembly and maintenance of the sarcomere night and day. Cardiovasc Res. 2008;77:667–675. doi: 10.1093/cvr/cvm048. [DOI] [PubMed] [Google Scholar]
  • 80.Collins HE, Rodrigo GC. Inotropic response of cardiac ventricular myocytes to beta-adrenergic stimulation with isoproterenol exhibits diurnal variation: involvement of nitric oxide. Circ Res. 2010;106:1244–1252. doi: 10.1161/CIRCRESAHA.109.213942. [DOI] [PubMed] [Google Scholar]
  • 81.Weil ZM, Karelina K, Su AJ, Barker JM, Norman GJ, Zhang N, Devries AC, Nelson RJ. Time-of-day determines neuronal damage and mortality after cardiac arrest. Neurobiol Dis. 2009;36:352–360. doi: 10.1016/j.nbd.2009.07.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Durgan DJ, Pulinilkunnil T, Villegas-Montoya C, Garvey ME, Frangogiannis NG, Michael LH, Chow CW, Dyck JR, Young ME. Short communication: ischemia/reperfusion tolerance is time-of-day-dependent: mediation by the cardiomyocyte circadian clock. Circ Res. 2010;106:546–550. doi: 10.1161/CIRCRESAHA.109.209346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol. 2010;106:893–901. doi: 10.1016/j.amjcard.2010.05.013. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES